CellWell record HH-458052
The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and Avapritinib
Piotr Kawczak; Tomasz Bączek
2026
In plain language
In patients with gastrointestinal stromal tumors, this review found that second- and third-generation tyrosine kinase inhibitors extended survival and offered mutation-specific treatment for advanced disease.
- Evidence
- Emerging
- Design
- Expert review
Cite this record: https://thecellwell.org/studies/HH-458052
Produced by the CellWell Research Engine, custom software owned and operated by CellWell. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.